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Autism spectrum disorder (ASD) is a behaviorally defined syndrome with 
frequent co-morbidities. Evidence indicate a role of innate immunity in ASD patho-
genesis. This study addressed whether innate immune abnormalities are associated 
with ASD co-morbid conditions and/or other clinical co-variables when assessed 
as changes in monocyte cytokine profiles. This study included 109 ASD (median 
11.5 year) and 26 non-ASD subjects (median 11.4 year). Monocyte cytokine profiles 
were evaluated in association with age/ethnicity, ASD severity, medications, and 
co-morbidities present in >15% of ASD subjects [gastrointestinal (GI) symptoms, 
epilepsy, allergic rhinitis, specific antibody deficiency (SAD), and fluctuating 
behavioral symptoms resembling pediatric acute-onset neuropsychiatric syndrome 
(PANS)]. ASD severity did not affect frequency of co-morbid conditions. GI symp-
toms, epilepsy, SAD, and PANS like symptoms revealed associations with changes in 
production of tumor necrosis factor-α (TNF-α)/soluble TNF-receptor II (sTNFRII), 
interleukin-1ß (IL-1ß)/IL-6/IL-10, and IL-6, respectively, mostly independent of 
other co-variables. ASD severity was associated with changes in multiple cytokines 
but frequently affected by other clinical co-variables. Our findings revealed associa-
tions between specific monocyte cytokine profiles and certain co-morbid condi-
tions in ASD subjects, independent of other clinical co-variables. Our findings will 
aid in assessing treatment options for ASD co-morbidities and their effects on ASD 
behavioral symptoms.
Keywords: autism spectrum disorder (ASD), co-morbid conditions, innate immune 
memory (IIM), monocyte cytokines, trained immunity
1. Introduction
Autism spectrum disorder (ASD) is a behavioral defined syndrome except for a 
small subset of patients with defined gene mutations such as MECP2 (Rett syn-
drome) and TSC1/TSC2 (tuberous sclerosis) [1, 2]. However, core ASD symptoms 
may be the results of the effects of various genetic and environmental factors that 
may also affect organs other than central nervous system (CNS). Consequently, 
medical conditions affecting other organs may also affect ASD symptoms, partly 
through pain and discomfort. This makes it difficult to have reliable objective 
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diagnostic measures universally applicable for ASD children. This assumption is 
supported by the fact that ASD is characterized by multiple co-morbid medical 
conditions, with GI symptoms being the most common [3, 4].
Many co-morbid conditions reported in ASD subjects are associated with 
immune mediated inflammation in pathogenesis; GI symptoms found in ASD sub-
jects have been in part implicated with chronic GI inflammation due to dysregulated 
gut immune responses to microbiota [5, 6]. Mounting evidence also indicates that 
many, but not all the ASD subjects show some immune abnormalities that affect 
almost every arm of the immune system [7, 8]. Moreover, given the fact that the 
immune system and the CNS interact closely interact [9], a role of neuroinflamma-
tion in ASD pathogenesis is highly suspected in a subset of ASD subjects.
In our previous studies, we focused on abnormalities of innate immunity, which 
plays a major role in the neuro-immune network including stress responses [10–12]. 
One of the reasons that we focused on innate immune abnormalities is based on 
findings from one of the most thoroughly studied animal models of ASD, maternal 
immune activation (MIA). MIA is induced by sterile stimulants of innate immunity 
in pregnant rodents [13]. MIA generates lasting effects on behavioral symptoms and 
the immune functions in offspring [13, 14]. It has been puzzling that how innate 
immunity, which lacks memory for specific antigens, can cause such lasting effects. 
However, discovery of innate immune memory (IIM) caused by initial stimuli 
through epigenetic regulations [15, 16], has helped us understand the lasting effects 
of dysregulated IIM in various inflammatory conditions. In fact, dysregulated IIM 
is now implicated in the pathogenesis of common neuropsychiatric diseases such as 
schizophrenia and depression [17, 18]. We found abnormalities of innate immunity 
in many, but not all the ASD subjects we studied by assessing cytokine profiles from 
purified monocytes [11].
Given both the considerable amount of abnormalities found in the monocyte 
cytokine profiles and the high frequency of co-morbid medical conditions in ASD 
subjects, questions understandably arise concerning the association of co-morbid 
conditions with changes in monocyte cytokine production. Many ASD subjects 
are treated with neurotropic medications including selective serotonin re-uptake 
inhibitors (SSRIs), anti-seizure medications used as mood stabilizers, neuroleptics, 
and medications for ADHD. These medications may also affect monocyte cytokine 
profiles. Therefore, this study addressed whether monocyte cytokine profiles differ 
depending on co-morbid conditions, ASD severity, and other clinical co-variables. 
The results indicate that co-morbid medical conditions are associated with changes 
in production of specific cytokines and such associated are not affected by other 
clinical co-variables.
2. Materials and methods
Study subjects: Study subjects were recruited following the study protocols 
(#17:53 and #19:53) approved by the institutional review. Signed consent forms 
were obtained prior to entering the study.
ASD subjects: ASD subjects (N = 109) were recruited from the Pediatric 
Allergy/Immunology Clinic at SPUH. Diagnosis of ASD was made at various autism 
diagnostic centers, including ours, based on the Autism Diagnostic Observation 
Scale (ADOS) and/or Autism Diagnostic Interview-Revisited (ADI-R), as well as 
other standard measures. ASD subjects were also evaluated for their behavioral 
symptoms and sleep habits with the Aberrant Behavior Checklist (ABC) [19] and 
the Children’s Sleep Habits Questionnaires (CSHQ ) [20], respectively. Information 
regarding cognitive ability and adaptive skills were obtained from previous school 
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evaluation records performed within 1 year of enrollment in the study; these results 
were based on standard measures such as the Woodcock-Johnson III test (for cogni-
tive ability), and Vineland Adaptive Behavior Scale (for adaptive skills) [21].
Non-ASD controls: A total of 26 non-ASD subjects served as controls. These 
subjects were recruited in the Pediatrics Subspecialty and General Pediatrics 
Clinics at our institution. These subjects were typically growing and satisfied our 
exclusion/inclusion criteria.
Demographics of study subjects were summarized in Table 1.
Diagnosis of food allergy (FA): IgE mediated FA was diagnosed with reactions 
to offending food, by affecting the skin, GI, and/or respiratory tract immediately 
(within 2 hours) after intake with positive prick skin testing (PST) reactivity, and/or 
presence of food allergen-specific serum IgE. Non IgE mediated FA (NFA) was diag-
nosed if GI symptoms resolved, following implementation of a restricted diet (i.e., 
avoidance of offending food), and symptoms recurred with re-exposure to offending 
food [22]. NFA was also defined as being non-reactive to PFT and negative for serum 
IgE specific for food allergens [22].
Diagnosis of asthma and AR: AR and allergic conjunctivitis (AC) were diagnosed 
when subjects had corresponding clinical features along with positive PST reactiv-
ity and/or positive serum IgE specific to causative allergens [23, 24]. Asthma was 
diagnosed following the asthma guidelines from the Expert Panel Report 3 [25].
Diagnosis of Antibody deficiency syndrome: When the subject revealed protective 
levels of antibodies in less than 11 of 14 serotypes of Streptococcus pneumonia after 
the booster dose of Pneumovax® or PCV13®, he/she was diagnosed with SAD [26]. 
Antibody levels greater than 1.3 μg/ml were considered protective [26].
Diagnosis of PANS like symptoms and sleep disorders: Pediatric acute-onset 
neuropsychiatric syndrome (PANS) is a clinical diagnosis [27]. Most ASD sub-
jects recruited to the study were diagnosed with PANS by other physicians. We 
attempted to validate the diagnosis based on the PANS diagnostic criteria [27]. In 
some ASD children, pre-existing neuropsychiatric symptoms made it difficult to 
apply the clinical diagnostic criteria of PANS. In this study, we categorized ASD 
patients with recurrent worsening behavioral symptoms following immune stimuli 
(typically microbial infection) more than 2×, not controlled by proper manage-
ment of triggering stimuli as ASD subjects with PANS like symptoms. Diagnosis of 
sleep disorders that lasts at least more than 6 weeks is based on parental reports and 
results of CSHQ .
Sample collection: Venous blood samples were obtained by the physician in this 
study. We obtained one sample from each non-ASD controls. As for ASD subjects, 
we obtained multiple blood samples at different time points from select ASD sub-





Gender 95 M, 15 F (Female 13.8%) 19 M, 7 F (Female 26.9%)
Age: Average ± SD (years)





Ethnicity 84 W, 5 AA, 19 Asian, 1 Mixed 22 W, 2 AA, 2 Mixed
Abbreviations used: AA; African American, ASD; autism spectrum disorders, SD; standard deviation,  
W; Caucasian.
Table 1. 
Demographics of study subjects.
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or study subjects preferred, we applied a topical lidocaine/prilocaine cream (Emla 
cream®) to the site of venipuncture prior to blood sampling.
Cell cultures: Ficoll–Hypaque density gradient centrifugation was used for 
separating PBMCs. From PBMCs, PBMo were further purified using a column of 
magnetic beads labeled with anti-CD3, CD7, CD16, CD19, CD56, CD123, and gly-
cophorin A (monocyte separation kit II – human, MILTENYI BIOTEC, Cambridge, 
MA, United States). Combination of these antibodies depletes T, B, natural killer, 
and dendritic cells from PBMCs.
Cytokine production by purified PBMo was induced by incubating cells over-
night (2.5 × 105 cells/ml) with a panel of agonists of TLRs. This assay system was 
designed to reflect the effects of microbial byproducts commonly encountered in 
real life. Lipopolysaccharide (LPS), a TLR4 agonist, represents a signaling pathway 
activated in response to a gram negative [G (−)] bacteria. Zymosan, a TLR2/6 
agonist, mimics an innate activation signal in response to G (+) bacteria and fungi. 
CL097, a TLR7/8 agonist, activates innate signaling pathways in response to ssRNA 
viruses that cause common respiratory infection. Candida heat extract as a source 
of ß-glucan, a dectin-1 agonist, was used as well as a C-lectin receptor agonist. 
PBMos were incubated overnight with LPS (0.1 μg/ml, GIBCO-BRL, Gaithersburg, 
MD, USA), zymosan (50 μg/ml, Sigma-Aldrich, St. Luis, Mo), C097 (water-soluble 
derivative of imidazoquinoline, 20 μM, InvivoGen, San Diego, CA, USA), and can-
dida heat extract (HCKA, heat killed Candida albicans (107 cells/ml, InVivogen, San 
Diego, CA) in RPMI 1640 with additives as previously described [28]. Overnight 
incubation (16-20 h) was adequate to induce the optimal responses in this set-
ting in previous studies [11]. Cytokine levels in the culture supernatant were then 
measured.
Levels of CCL2, IL-1β, IL-6, IL-10, IL-12p40, transforming growth factor-ß 
(TGF-ß), tumor TNF-α, and sTNFRII cytokines were measured by enzyme-linked 
immuno-sorbent assay (ELISA); 10–100 μl/well supernatants were used for ELISA. 
The OptEIA™ Reagent Sets (BD Biosciences, San Jose, CA, USA) were used for 
ELISA of IL-1ß, IL-6, IL-10, IL-12p40, and TNF-α. For CCL2, sTNFRII, and TGF-ß 
ELISA, reagents were obtained from BD Biosciences and R & D (Minneapolis, MN, 
USA). IL-23 ELISA kit was purchased from eBiosciences, San Diego, CA. Intra- and 
inter-variations of cytokine levels were less than 5%.
Statistical analysis: We used a two tailed Mann–Whitney test for comparison 
of two sets of numerical data. Kruskal-Wallis test was used for comparison of more 
than 2 sets of numerical data. When assessing differences in frequency between two 
groups, we used the Fisher exact test. For assessing differences in frequency among 
multiple groups, we used the Chi-square test and the Likelihood ratio. P value of 
less than 0.05 was considered nominally significant. Co-variance analysis was done 
with the use of analysis of variance (ANOVA) for a fixed factor or for a variable 
factor. NCSS2020 (NCSS, LLC. Kaysville, UT) was used for such statistical analysis.
3. Results
Clinical characteristics: Frequencies of co-morbid conditions among the 
recruited ASD subjects are summarized in Table 2. These results are consistent with 
the results of our previous studies [12, 29]. Age and gender were not associated with 
ASD severity (data now shown). Frequencies of co-morbid conditions and the use 
of neurotropic medications did not differ due to ASD severity in 108 ASD subjects 
who were verified ASD severity (Table 3).
Changes in monocyte cytokine production depending on ASD severity: We 
then examined whether monocyte cytokine profiles differed with ASD severity 
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and if such changes were affected by other clinical co-variables. ASD severity was 
shown to be associated with changes in production of TNF-α, IL-1ß, IL-10, and 
CCL2, and TNF-α/sTNFRII ratios (Table 4). However, production of inflamma-
tory monocyte cytokines (TNF-α and IL-1ß) under several culture conditions is 
affected by presence of co-morbid conditions and the use of ADHD medications 
(Table 4).
Changes in monocyte cytokine production depending on co-morbid  
conditions: Since associations between ASD severity and monocyte cytokine 
profiles were often affected by other co-morbid conditions and medication use 
(Table 4), we also evaluated whether changes in monocyte cytokine profiles in ASD 
subjects were affected by the presence of co-morbid conditions.
Co-morbid conditions with objective diagnostic measures: We evaluated changes in 
monocyte cytokine profiles in association with co-morbid conditions which were 
Comorbid conditions ASD subjects (N = 109) Controls (N = 26)
GI1 symptoms 71/109 (65.1%) 0
history of NFA 68/109 (63.4%) 2/26 (7.7%)
Seizure disorders 18/109 (16.5%) 0
Asthma 5/109 (4.6%) 0
Allergic rhinitis 17/109 (15.6%) 0
Specific antibody deficiency 26/109 (23.9%) 0
PANS like symptoms 62/109 (56.9%) 0
Disturbed Sleep 48/109 (44.0%) 0
1Abbreviations used: ASD; autism spectrum disorder, GI; gastrointestinal, NFA; non-IgE mediated food allergy, 
PANS; pediatric acute-onset neuropsychiatric syndrome.
Table 2. 
Frequency of comorbid conditions in the study subjects.
ASD1 severity Level 1 Level 2 Level 3 Chi-Square
Co-morbid conditions
GI symptoms 14/272 20/32 36/49 p > 0.1
Seizure disorder 1/27 6/32 10/49 p = 0.081
Antibody deficiency 6/27 10/32 10/49 p > 0.1
PANS like symptoms 12/27 19/32 30/49 p > 0.1
Disturbed sleep 8/27 16/32 23/49 p > 0.1
Medications
SSRIs 6/27 8/32 4/49 p > 0.1
Anti-seizure medications 3/27 9/32 8/49 p > 0.1
ADHD medications 3/27 3/32 3/49 p > 0.1
Neuroleptics 4/27 1/32 9/49 p = 0.079
1Abbreviations used: ASD; autism spectrum disorder, GI; gastrointestinal, NFA; non-IgE mediated food allergy, 
ADHD: attention deficiency hyperactivity disorder, PANS; pediatric acute-onset neuropsychiatric syndrome, SSRI: 
selective serotonin reuptake inhibitor.
2One ASD subject was excluded from this analysis due to lack of validation of ASD severity.
Table 3. 
Frequencies of Co-morbid conditions and medication use did not differ due to ASD severity.
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evaluated with objective measures as defined in the method section. We found 
that such co-morbid conditions were observed in more than 15% of our ASD study 
subjects; these include GI symptoms, seizure disorders, AR, and SAD. Our results 
revealed that there are significant associations between monocyte cytokine produc-
tion and ASD co-morbid conditions as described above (Table 5). Presence of GI 
symptoms are mainly associated with changes in TNF-α production and the ratio 
of TNF-α/sTNFRII ratios under several culture conditions. Co-variance analysis 
showed that these parameters were mostly not affected by other clinical co-vari-
ables including medication use. The exceptions are TNF-α production and TNF-α/
sTNFRII ratios under zymosan stimulated cultures, which are affected by ASD 
severity (Table 5). Diagnosis of seizure disorders was the most notably associated 
with changes in IL-1ß production and IL-1ß/IL-10 ratios under the CL097 stimu-
lated cultures, independent of clinical co-variables that we assessed (Table 5). The 
AR diagnosis is mainly associated with changes in sTNFRII production. The SAD 
diagnosis is mainly associated with changes in IL-6 and IL-10 production. Most of 
these cytokine parameters were again not affected by the other clinical variables 
that we assessed.
Co-morbid conditions based on clinical diagnosis: Although assessment of PANS 
like symptoms and sleep disorder were diagnosed without objective measures, 
given the high frequency of these conditions, we also assessed differences in 
monocyte cytokine parameters in association with these two co-morbid condi-
tions. Significant differences in certain monocyte cytokine parameters were found 
in the presence of PANS like symptoms and sleep disorders (Table 6). PANS like 
conditions were associated with changes in inflammatory cytokines (IL-6 and 
IL-1ß), as well as sTNFRII and CCL2. Only IL-1ß production was affected by other 
clinical covariables. As for sleep disorders, changes in TGF-ß levels were mainly 
associated with the presence of sleep disorders and changes in TGF-ß productions 












N = 33 N = 37 N = 52
TNF-α (CLO97)1 2390.2 ± 1786.9 2720.2 ± 983.3 2073.0 ± 1171.6 p < 0.01
IL-10 (CLO97) 1318.1 ± 595.3 918.2 ± 576.1 1009.9 ± 607.2 p < 0.05
TNF-α/sTNFRII 
(CLO97)2
3.78 ± 3.34 8.43 ± 10.43 8.73 ± 17.27 p < 0.05
TNF-α (ß-glucan)3 1816.2 ± 1139.4 2360.4 ± 1249.9 1512.2 ± 883.9 p < 0.005
IL-1ß (ß-glucan)4 2578.7 ± 922.0 2809.7 ± 984.4 2062.9 ± 949.7 p < 0.005
TNF-α (ß-glucan+LPS)1 2338.0 ± 259.0 2658.4 ± 984.5 2000.2 ± 916.5 p < 0.01
CCL2 (ß-glucan+LPS) 2708.0 ± 2477.4 1758.6 ± 16681 1574.8 ± 1553.1 p < 0.05
CCL2 (zymosan) 9105.2 ± 6631.1 7668.4 ± 4973.2 5870.3 ± 4414.4 p < 0.05
1ANOVA co-variance analysis revealed an association with the use of ADHD medications (p < 0.02 and p < 0.05 
under culture conditions stimulated with CL097 and ß-glucan+LPS, respectively).
2ANOVA co-variance analysis revealed an association with GI symptoms (p < 0.05).
3ANOVA co-variance analysis revealed an association with PANS like symptoms (p < 0.05).
4ANOVA co-variance analysis revealed an association with Disturbed sleep (p < 0.05).
5Abbreviations used: CCL2; C-C chemokine ligand 2, IL; interleukin, LPS; lipopolysaccharide, TNF; tumor necrosis 
factor.
Table 4. 






































Comorbid conditions ASD1 with comorbid condition ASD without comorbid condition Non-ASD Control Kruskal-Wallis test
GI symptoms N = 81 N = 42 N = 26
TNF-α (LPS) 685.1 ± 744.83 373.0 ± 366.5 474.4 ± 505.8 p < 0.01
TNF-α (zymosan)2 1498.8 ± 1055.6 1047.6 ± 709.6 1609.7 ± 748.3 p < 0.01
TNF-α (ß-glucan) 1961.6 ± 1108.2 1609.7 ± 1135.7 1931.1 ± 948.5 p = 0.113
TNF-α/sTNFRII (LPS) 0.69 ± 0.89 0.50 ± 1.27 1.28 ± 3.53 p < 0.05
TNF-α/sTNFRII (zymosan)2 2.98 ± 2.61 2.67 ± 5.68 3.54 ± 3.61 p < 0.05
TNF-α/sTNFRII (ß-glucan) 6.84 ± 6.79 3.88 ± 2.31 13.5 ± 18.0 p < 0.01
Seizure disorders N = 24 N = 99 N = 26
IL-1ß (CL097) 3732.3 ± 1092.8 4566.4 ± 1357.5 3715.5 ± 1367.9 p < 0.01
IL-1ß/IL-10 (CL097) 5.10 ± 7.98 8.98 ± 12.44 3.98 ± 2.53 p < 0.001
TNF-α/sTNFRII 3.89 ± 6.74 8.04 ± 13.74 4.31 ± 3.48 p < 0.02
(CL097) CCL2 18862 ± 19577 14588 ± 9672 11499 ± 7621 p < 0.02
(CL097) IL-1ß (ß-glucan) 1955.9 ± 996.9 2546.4 ± 972.1 21767.0 ± 999.9 p = 0.056
Allergic rhinitis N = 20 N = 103 N = 26
sTNFRII (LPS) 1538.1 ± 395.5 1284.0 ± 493.7 1172.5 ± 504.2 p < 0.05
IL-1ß (CL097)2 5038.3 ± 1368.3 4285.8 ± 1315.6 3715.5 ± 1357.9 p < 0.01
sTNFRII (ß-glucan)2 497.8 ± 225.2 414.1 ± 286.6 340.8 ± 257.7 p < 0.05
sTNFRII (LPS + ß-glucan) 488.8 ± 249.4 392.5 ± 297.3 371.6 ± 354.3 p = 0.07179
Antibody deficiency N = 31 N = 92 N = 26
IL-6 (medium) 2303.5 ± 1935.8 3869.2 ± 2581.629553 ± 18279 3373.3 ± 1562.9 p < 0.01
IL-6 (LPS) 19536 ± 9625 6309.2 ± 1974.7 20152 ± 12909 p < 0.01



















Comorbid conditions ASD1 with comorbid condition ASD without comorbid condition Non-ASD Control Kruskal-Wallis test
IL-1ß (medium) 214.5 ± 253.3 646.6 ± 503.0 270.3 ± 185.9 p < 0.05
IL-10 (medium) 328.3 ± 336.4 1471.8 ± 417.9 597.1 ± 355.7 p < 0.005
IL-10 (LPS)2 1215.8 ± 539.2 620.1 ± 375.3 1200.0 ± 543.7 p < 0.05
IL-10 (zymosan) 506.3 ± 399.8 1150.0 ± 605.8 651.4 ± 380.2 p = 0.128
IL-10 (CL097) 863.2 ± 570.6 426.4 ± 354.6 1093.0 ± 579.5 p = 0.07
IL-12 (zymosan) 302.2 ± 290.3 360.7 ± 425.0 p = 0.1206
1Abbreviations used: ASD; autism spectrum disorder, GI; gastrointestinal, IL; interleukin, LPS; lipopolysaccharide, TNF; tumor necrosis factor.
2Co-variance analysis revealed that changes in TNF-α and TNF-α/sTNFRII (zymosan) production with GI symptoms are affected by ASD severity (p < 0.05). Changes in sTNFRII production (ß-glucan) 
with allergic rhinitis was affected with the use of anti-seizure medications (p < 0.05). Changes in production of IL-6 (zymosan) and IL-10 production (LPS) with antibody deficiency was affected with the 
use of neuroleptics/SSRIs and PANS like symptoms.
3The results were expressed as a mean ± SD. Cytokine levels were shown as pg/ml.
Table 5. 
Differences in monocyte cytokine production in association with GI symptoms, seizures disorders, allergic rhinitis, and antibody deficiency in ASD subjects.
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4. Discussion
ASD subjects suffer from multiple co-morbid conditions. However, we know little 
about how the presence of co-morbid conditions are associated with ASD pathogen-
esis. Core ASD symptoms used for diagnosis such as irritability, hyperactivity, self-
injurious behaviors, etc. can be affected by discomfort and pain caused by co-morbid 
medical conditions. In addition, recently, mounting evidence indicates a pathogenetic 
association between GI symptoms and the onset/progress of ASD [5, 9]. This may 
also be true for other common co-morbid conditions such as seizure disorders.
Unfortunately, impaired expressive language in ASD subjects make it more 
difficult to diagnose co-morbid medical conditions. For example, sinus headache 
caused by untreated sinusitis and AR can aggravate head banging and aggres-
sion (pinching others, etc.). Too often, such behaviors are dismissed as just being 
autistic, and diagnostic and treatment measures for common childhood diseases 
may not be properly sought in ASD children [30]. Considering the fact current ASD 
diagnosis is based on behavioral symptoms, the presence of co-morbid medical 
conditions may hold a key to assess pathogenesis in markedly heterogeneous ASD 
subjects and their variable behavioral symptoms.
When addressing the importance of co-morbid conditions frequently seen 
in ASD subjects, the role of immune mediated inflammation likely needs to be 










PANS like symptoms N = 73 N = 50 N = 2
IL-6 (CL097) 6747.6 ± 1939.23 7795.3 ± 1824.6 6325.5 ± 2011.2 p < 0.005
IL-6 (ß-glucan) 5502.2 ± 1725.7 6211.1 ± 1731.7 5230.4 ± 1706.7 p < 0.05
IL-6 (ß-glucan+LPS) 6505.7 ± 1654.5 7661.9 ± 1943.0 5756.6 ± 1875.3 p < 0.00001
IL-1ß (ß-glucan+LPS)2 3176.5 ± 1278.1 3706.3 ± 1029.4 2545.7 ± 987.1 p < 0.001
sTNFRII (zymosan) 618.2 ± 350.1 723.0 ± 293.6 663.7 ± 368.1 p = 0.069
CCL2 (zymosan) 6717.1 ± 5609.0 8055.4 ± 4899.3 6138.5 ± 6351.9 p < 0.05
Sleep disorders N = 56 N = 67 N = 26
IL-10 (LPS)2 1289.6 ± 499.9 1497.9 ± 422.6 1200.0 ± 543.7 p < 0.05
sTNFRII (LPS)2 1228.6 ± 473.4 1410.4 ± 484.6 1172.5 ± 551.9 p < 0.05
TGF-ß (medium) 535.1 ± 469.6 685.1 ± 443.1 398.0 ± 372.1 p < 0.01
TGF-ß (LPS) 545.7 ± 498.1 689.8 ± 436.2 372.8 ± 340.1 p < 0.005
TGF-ß (zymosan) 429.2 ± 415.4 542.8 ± 356.7 285.9 ± 287.0 p < 0.001
TGF-ß (CLO97) 459.3 ± 442.9 613.7 ± 421.0 325.8 ± 299.2 p < 0.005
TGF-ß (ß-glucan) 370.4 ± 335.7 518.4 ± 345.7 259.7 ± 280.8 p < 0.0005
1Abbreviations used include: IL; interleukin, LPS, lipopolysaccharide, PANS; pediatric acute-onset neuropsychiatric 
syndrome, TGF, transforming growth factor, TNF; tumor nectrosis factor, sTNFRII; soluble TNF receptor II.
2Changes in IL-1ß (ß-glucan+LPS) production with PANS like symptoms are affected with ASD severity. Changes in 
IL-10 and sTNFRII production with LPS was affected by ASD severity (p < 0.01) and Seizure disorder (p < 0.05). 
Changes in production of IL-10 (LPS) with sleep disorder is affected with the use of SSRIs (p < 0.005), and specific 
antibody deficiency and PANS like behaviors (p < 0.05) by co-variance analysis. sTNFRII production with sleep 
disoders are affected with the use of SSRIs (p < 0.005) by co-variance analysis.
3The results were expressed as a mean ± SD. Cytokine levels were shown as pg/ml.
Table 6. 
Differences of monocyte cytokine profiles with presence of PANS like symptoms and sleep disorders in ASD 
subjects.
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considered as a common denominator. The immune system has long been thought 
to play a role in neuroinflammation and is implicated with pathogenesis of ASD. 
One of the most extensively studied animal models of ASD is MIA, in which, ASD 
like behavioral changes in offspring are induced by sterile immune activation 
through stimuli of innate immunity given to pregnant rodents [13]. Discovery 
of IIM [15, 17] shed a light on the lasting effects of sterile, antigen non-specific 
inflammation generated in the MIA model. IIM is thought to be generated through 
epigenetic changes [17] and such changes created in fetal and early infancy could 
make such individuals more susceptible to common inflammatory conditions 
such as food induced enterocolitis syndrome (FPIES), a condition that were found 
frequently in ASD subjects in our clinic. Altered IIM skewed to pro-inflammatory 
responses may cause dysregulated responses to commensal microbiota in the 
gut, causing chronic GI inflammation, resembling inflammatory bowel diseases 
(IBD). Such changes in innate immune responses may lead to aberrant responses 
to respiratory microbes, resulting in altered clinical manifestations, as well. Such 
dysregulated innate immune responses to immune stimuli can also affect the brain, 
since many signaling pathways associated with innate immunity have roles in the 
nervous system [17].
Despite progress of our understanding of IIM, we do not know which innate 
immune parameters are associated with co-morbid medical conditions and how 
these parameters are associated with ASD severity. IIM is closely associated with 
changes in monocyte cytokine profiles [16]. Previously, we have found signifi-
cant changes in monocyte cytokine profiles in a subset of ASD patients [10, 11]. 
Therefore, this study addressed whether the specific monocyte cytokine parameters 
are associated with ASD co-morbid conditions. In this study, we randomly screened 
monocyte cytokine profiles in ASD subjects recruited to the study. In our clinic, 
because of the allergy/immunology specialty, we likely recruited more ASD subjects 
with co-morbid medical conditions. However, we reasoned that such potentially 
skewed ASD study subjects may make it easier for us to find specific monocyte 
markers associated with co-morbid conditions.
We found changes in certain monocyte cytokine parameters had an association 
with ASD severity (Table 4). However, parameters associated with inflammatory 
responses (production of TNF-α and IL-1ß, and TNF-α/sTNFRII ratio) were also 
found to be affected by other clinical co-variables including GI symptoms, and 
PANS like behaviors (Table 4). This finding seems to support our initial assump-
tion that associations between ASD behavioral symptoms and changes in monocyte 
cytokine profiles are affected by other clinical co-variables.
Therefore, we decided to assess changes of monocyte cytokine parameters in 
association with co-morbid conditions frequently found in ASD subjects. We found GI 
symptoms along with NFA or FPIES like conditions in ASD subjects at high frequency 
(>60%), which was consistent to our previous studies [10, 12, 29]. Most of the ASD 
patients with GI symptoms had a history of FPIES like symptoms (Table 2). In these 
patients, we found changes in production of TNF-α and TNF-α/sTNFRII ratios in 
association with GI symptoms, but to our surprise, we did not find any associations 
with other inflammatory markers typically associated with neuroinflammation. It may 
be that GI symptoms are mainly driven TNF-α mediated inflammation in these ASD 
subjects as seen in patients with IBD [31]. Our finding may indicate the possibility that 
treatment measures typically used for IBD patients may be applicable for treating GI 
symptoms in ASD. Interestingly, TNF-α production under zymosan mediated cultures 
was affected by ASD severity; this may provide further support of the gut-brain axis 
concept [5, 6].
As for seizure disorders, we found changes in IL-1ß production under the cul-
tures stimulated with ß-glucan and CLO97 in ASD subjects with seizure disorders 
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(Table 5). This association was independent of any other clinical co-variables by 
co-variance analysis. IL-1ß has been implicated with a major inflammatory compo-
nent in febrile seizures and is also implicated in the pathogenesis of seizures associ-
ated with neuroinflammation [32, 33]. These results may indicate utility of IL-1ß 
blockers for controlling seizures in ASD subjects, if control is not well achieved by 
the 1st line anti-seizure medications. This finding is also intriguing because we have 
found better control of seizures with the use of IL-1ß blockers in some ASD subjects 
previously [34].
The presence of AR appeared to be associated with an increase in sTNFRII levels 
which may be indicative of increase in counter-regulatory measures for allergic 
inflammation. However, since the numbers of AR patients in this study was rela-
tively low, these results need to be validated in future studies.
Our ASD study subjects included a fair number of ASD subjects with SAD 
(Table 2). These ASD subjects revealed lower production of IL-6 and IL-10 under 
several culture conditions (Table 5). Two of these parameters were affected by 
the presence of PANS like symptoms. This may not be surprising, since in our 
experience, we often observe a high frequency of SAD in non-ASD PANS patients. 
Interestingly, ASD subjects with PANS like behavioral symptoms also revealed 
lower production of IL-6 (Table 6). IL-6 is associated with terminal differentia-
tion of B cells and is reported to be lower in patients with antibody deficiency such 
as common variable immunodeficiency [35]. On the other hand, IL-6 has also be 
implicated with neuronal development, following neuronal insult during fetal 
and newborn periods [36, 37]. Reduced IL-6 production may reflect subsequent 
suppression, following prior IL-6 mediated neuroinflammation. If so, lowering 
IL-6 production may have evolved into impaired antibody production in some ASD 
subjects who had suffered from IL-6 mediated inflammation in their early years.
In subjects with autoimmune encephalitis refractory to rituximab, IL-6 blockers 
such as tocilizumab which is an inhibitor of the IL-6 receptor, are reported to be 
effective [38, 39]. However, in ASD subjects with lower IL-6 production, the use 
of IL-6 blockers may not be effective, even if the PANS like behavioral symptoms 
are attributed to AE. IL-10 production was also lower in ASD patients with SAD, 
however this is not associated with the presence of PANS like symptoms. Changes in 
IL-10 production is reported in patients with common variable immunodeficiency 
(CVID) [40]. Therefore, this finding may be associated with the pathogenesis of 
antibody deficiency.
When we assessed associations between sleep disorders and changes in monocyte 
cytokine profiles, we expected to see changes in inflammatory monocyte cytokines, 
since ASD subjects with PANS like symptoms often suffer from sleep disorders. 
However, we mainly found lower production of TGF-ß which is considered to be a 
counter-regulatory cytokine and associated with tissue repair, promoting fibrotic 
changes [41]. Our results may indicate a decrease in counter-regulatory measures in 
neuroinflammation in sleep disorders in ASD subjects. The etiology of and the role 
neuroinflammation plays in sleep disorders in ASD are not well understood. Our 
finding may indicate that impairment of TGF-mediated pathways may play a role in 
sleep disorders in ASD.
Our previous studies indicated that IL-1ß/IL-10 ratios can be general markers 
for dysregulatred innate immune responses in ASD subjects [12]. However, in this 
study, we did not find strong associations with this parameter to specific co-
morbid medical conditions, except for seizure disorder. This parameter may be 
associated with general inflammation caused by immune mediated inflammation. 
However, in order to more fully assess treatment options for co-morbid medical 
conditions in ASD subjects, detailed analysis of monocyte cytokine profiles is 
likely required.
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Our study may be limited by the relatively small sample side of ASD subjects 
who had specific co-morbid conditions. Findings in this study need to be validated 
by a study using a larger numbers of study subjects, in association with responses to 
specific treatment measures targeted to each co-morbid condition.
5. Conclusion
Our study revealed that associations between monocyte cytokine parameters 
and specific co-morbid medical conditions exist in the ASD subjects studied, 
independent of other clinical variables. This indicates that there is a possibility that 
monocyte cytokine profiles may be used for assessing treatment options in ASD 
subjects with specific co-morbid medical conditions.
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AA African American
ABC aberrant behavior checklist
AC allergic conjunctivitis
ADHD attention deficiency hyperactivity disorder
ADI-R autism diagnostic interview-revisited
ADOS autism diagnostic observation scale
AR allergic rhinitis
ASD autism spectrum disorder
CCL2 C-C chemokine ligand 2
CSHQ children’s sleep habits questionnaires
CNS central nervous system
CVID common variable immunodeficiency
FA food allergy
FPIES food induced enterocolitis syndrome
GI gastrointestinal
IBD inflammatory bowel disease
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IL interleukin
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PANS pediatric acute-onset neuropsychiatric syndrome
PBMo peripheral blood monocytes
PST prick skin testing
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